Pfizer is a Buy at low valuation but faces a 2030 patent cliff, COVID sales declines, and LOE risks. Click here to read an ...

Pfizer is preparing for a consumer market for obesity drugs on par with the booming business it saw after it launched ...

At J.P. Morgan 2026, Pfizer CEO Albert Bourla positioned the company as a post-COVID operator focused on disciplined ...

Pfizer Inc. (NYSE: PFE) is included among the 13 Best Dividend Stocks Paying Over 6%.

Diversification is key to successful long-term investing. In other words, don't put all your eggs in one basket.

Royalty Pharma plc (Nasdaq: RPRX) today announced that its board of directors has declared a dividend for the first quarter of 2026 of $0.235 per Class A ordinary share, reflecting a 6.8% increase in ...

Dow Jones Industrial Average, Chevron Corp, Coca-Cola Co, Merck & Company Inc. Read 's Market Analysis on Investing.com ...

The vaccines subsector received a big fillip from Covid, but its potential extends far beyond combating pandemics. Dr Mike ...

There are few more hated stocks than UnitedHealthcare, the biggest health insurer. Among its other well-known problems, the ...

These five high-yield dividend stocks with solid upside potential and Buy ratings make sense for growth and income investors ...

Investing $12,000 in the stock today would allow you to collect approximately $600 in dividends per year. Combined with the ...

Despite additional cost savings in 2026, Pfizer also forecasts that its adjusted earnings per share (EPS) will likely decline ...